{"id":"glucobay-acarbose","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"15-25","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:50:34.998167","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acarbose is an alpha-glucosidase inhibitor that competitively binds to enzymes in the brush border of the small intestine, delaying the breakdown of disaccharides and complex carbohydrates into monosaccharides. This delays glucose absorption and results in lower postprandial glucose levels in patients with type 2 diabetes. The drug does not stimulate insulin secretion and works through a local gastrointestinal mechanism.","oneSentence":"Acarbose slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:24.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(4533)"],"trialDetails":[{"nctId":"NCT05542849","phase":"PHASE4","title":"The Efficacy and Tolerability of Acarbose in Healthy Individuals","status":"COMPLETED","sponsor":"AgelessRx","startDate":"2022-08-10","conditions":"Tolerance, Side Effect, Glucose Response","enrollment":15},{"nctId":"NCT00909051","phase":"","title":"GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03-24","conditions":"Diabetes Mellitus","enrollment":15729},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03794336","phase":"PHASE4","title":"Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-06-29","conditions":"Type 2 Diabetes Mellitus","enrollment":1293},{"nctId":"NCT01914133","phase":"PHASE2","title":"Acarbose and Older Adults With Postprandial Hypotension","status":"COMPLETED","sponsor":"Kenneth Madden","startDate":"2014-01","conditions":"Other Specified Hypotension, Syncope","enrollment":42},{"nctId":"NCT04065581","phase":"PHASE1","title":"Bioequivalence Study for Acarbose/Metformin FDC","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-14","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT03241303","phase":"NA","title":"Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-08-01","conditions":"Glucose Metabolism Disorders","enrollment":15},{"nctId":"NCT02049814","phase":"PHASE4","title":"Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":494},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT02315495","phase":"PHASE3","title":"Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes","status":"COMPLETED","sponsor":"Zilin Sun","startDate":"2015-04-03","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT02527993","phase":"PHASE4","title":"Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2015-10","conditions":"Hypoglycemia, Obesity, Surgery","enrollment":11},{"nctId":"NCT00829660","phase":"PHASE4","title":"Acarbose Cardiovascular Evaluation Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-02-17","conditions":"Coronary Heart Disease, Acute Coronary Syndrome, Impaired Glucose Tolerance","enrollment":6526},{"nctId":"NCT02243176","phase":"PHASE4","title":"24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":689},{"nctId":"NCT00568074","phase":"PHASE4","title":"Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":131},{"nctId":"NCT02999841","phase":"PHASE4","title":"Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":100},{"nctId":"NCT01961388","phase":"","title":"Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2015-08","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT01915264","phase":"","title":"GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2015-08","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02605772","phase":"PHASE4","title":"Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT02438397","phase":"PHASE4","title":"the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin","status":"UNKNOWN","sponsor":"Shanghai 6th People's Hospital","startDate":"2014-12","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT02355509","phase":"PHASE4","title":"Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2010-01","conditions":"Glucose Intolerance, Postprandial Hyperglycemia, Cardiovascular Risk Factor","enrollment":21},{"nctId":"NCT01685502","phase":"","title":"Special Drug Use Investigation of Glucobay OD","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-11","conditions":"Diabetes Mellitus","enrollment":2289},{"nctId":"NCT02211950","phase":"PHASE1","title":"Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Healthy","enrollment":37},{"nctId":"NCT01612741","phase":"","title":"Diabetes Treatment With Glucobay in Combination With Metformin","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":19509},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT01219582","phase":"","title":"GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":9364},{"nctId":"NCT01388153","phase":"PHASE1","title":"A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06","conditions":"Diabetes Mellitus, Type 2","enrollment":33},{"nctId":"NCT01613105","phase":"","title":"Diabetes Treatment With Glucobay in Combination With Sulfonylurea","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":4564},{"nctId":"NCT01248481","phase":"","title":"GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Diabetes Mellitus","enrollment":539},{"nctId":"NCT01554631","phase":"PHASE1","title":"A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Diabetes Mellitus, Type 2","enrollment":34},{"nctId":"NCT01758471","phase":"PHASE4","title":"Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-12","conditions":"Type 2 Diabetes","enrollment":160},{"nctId":"NCT01728740","phase":"PHASE1","title":"Bioequivalence Study for Acarbose / Metformin FDC","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Diabetes Mellitus, Type II","enrollment":40},{"nctId":"NCT00858676","phase":"PHASE4","title":"Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2009-04","conditions":"Diabetes Mellitus, Impaired Glucose Tolerance, Coronary Artery Disease","enrollment":150},{"nctId":"NCT00928889","phase":"PHASE4","title":"Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":160},{"nctId":"NCT01333774","phase":"","title":"Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Diabetes Mellitus","enrollment":423},{"nctId":"NCT01175486","phase":"PHASE4","title":"Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2010-07","conditions":"Diabetes","enrollment":200},{"nctId":"NCT01010100","phase":"PHASE3","title":"Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2000-08","conditions":"Diabetes Mellitus","enrollment":204},{"nctId":"NCT01167231","phase":"","title":"Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Diabetes Mellitus","enrollment":3310}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HYPOGLYCAEMIA"},{"count":2,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":2,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":2,"reaction":"COUGH"},{"count":2,"reaction":"HYPOALBUMINAEMIA"},{"count":2,"reaction":"HYPOGLYCAEMIC UNCONSCIOUSNESS"},{"count":2,"reaction":"INFECTION"},{"count":2,"reaction":"PLEURAL EFFUSION"},{"count":2,"reaction":"RENAL FAILURE"},{"count":1,"reaction":"ACUTE RESPIRATORY DISTRESS SYNDROME"}],"_approvalHistory":[],"publicationCount":4533,"recentPublications":[{"date":"2026 Feb 25","pmid":"41901199","title":"Cycloartane-Type Saponins, Phytochemical-Rich Extracts, and Sub-Extracts from Astragalus noeanus Boiss. Exhibit In Vitro and In Silico Effects on Glucose Metabolism.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 14","pmid":"41901098","title":"Loquat Flowers Exceed Leaves: A Less Explored Phenolic Source with Functional Potential.","journal":"Nutrients"},{"date":"2026 Mar 23","pmid":"41901049","title":"Integrative Pharmacological and Computational Analysis of Abelmoschus esculentus Phytochemicals: Enzyme Inhibition, Molecular Docking, and Dynamics Simulation Against Key Antidiabetic Targets.","journal":"Life (Basel, Switzerland)"},{"date":"2026 Mar 17","pmid":"41898588","title":"Synthesis of Antioxidative p-Terphenyl Dimers via Boronic Acid-Mediated C-C Coupling.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 11","pmid":"41898451","title":"Anti-Hyperglycemic and Antioxidant Effects of Sclerocarya birrea Leaf Crude Extract and Biosynthesized Silver Nanoparticles In Vitro.","journal":"International journal of molecular sciences"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glucobay"],"phase":"marketed","status":"active","brandName":"Glucobay (acarbose)","genericName":"Glucobay (acarbose)","companyName":"Zealand University Hospital","companyId":"zealand-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acarbose, also known as Glucobay, is a small molecule used to treat type 2 diabetes mellitus. It is studied in combination with other treatments, such as metformin and sitagliptin, as part of various clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}